Articles On Imugene (ASX:IMU)

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

The ASX 200 Health Index (XHJ) is trading higher by 0.30% at the time of writing, compared to the broader index which is also up by 0.87%. Imugene (ASX:IMU) is up by 8% this morning, after confirming that its immunotherapy candidate, PD1-Va...

Imugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on to the combination dose escalation The PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer The tria...

“Our Phase 1a trial has been open 12 months and I’m pleased with both the pace of development and the early responses seen. It’s particularly gratifying to have followed a patient in the trial for over 12 months where their tumour burden ha...

It was the last full trading session for the ASX in 2021, and the local benchmark index closed flattish, just 0.04% higher at 7,512. The move followed S&P 500’s 70th record close overnight, with the Dow Jones also hovering at all time h...

The Santa rally overcame a mid-session wobble to deliver investors a sixth straight rise and a 16-week closing high on the last full trading session of 2021. The S&P/ASX 200 rallied in the final hour to a slender gain of 3.6 points o...

The share market drifted lower amid signs of buyer fatigue following a five-session rally across the Christmas break. The S&P/ASX 200 inched to a 16-week high before rolling over. By mid-session, the Australian benchmark was off eigh...

Highlights The ASX 200 was trading 1.6 points up at 7,511.4 in early trade. As Asia markets closed in the red on Wednesday, European stock markets closed mixed. The utilities sector is the biggest laggard today, falling 1.3%. The...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Highlights The ASX 200 advanced 0.1 per cent, or 9.8 points, to 7364.8  today. Asian shares were mostly higher, following the positive session of the Wall Street overnight. Bitcoin, the largest cryptocurrency by market value, has risen...

A strong tech-led rebound on Wall Street overnight wasn’t enough to provide a boost for the ASX 200. The local index finished Wednesday flattish, with Real Estate being the main laggard, falling by 1.3%. The property sector retreated as NAB...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The S&P/ASX 200 Index (ASX: XJO) is having a decent day of trading on the markets this Tuesday so far, nicely countering yesterday’s shaky start to the trading week. At the time of writing, the ASX 200 is up a healthy 0.75% at 7,347 po...

The share market shrugged off weak leads and record Covid numbers in NSW as robust consumer confidence data suggested Australians were learning to live with omicron and the Prime Minister ruled out further lockdowns. The S&P/ASX 200...

The ASX 200 started Christmas week in the red today, down by 0.27%, as investors turned increasingly cautious around the societal ramifications of Omicron. PM Scott Morrison has just called for a snap cabinet meeting to deal with the latest...

Today, the S&P/ASX 200 Index (ASX: XJO) took a trip to the downside amid key data from the Reserve Bank of Australia (RBA). Once again, RBA governor Philip Lowe rejected forecasts that the central bank will look to raise rates next yea...

The Tech sector weighed heavily on the local index today and was down by more than 2.5%, dragging the ASX 200 lower by 0.70%. The fall came on the back of negative sentiment on the Nasdaq overnight, which fell by more than 1%. Investors hav...

The ASX 200 eked out a small Tuesday gain, as local stocks drifted sideways following a weak lead from Wall Street. There wasn’t much happening on the macro front to drive any sector much higher or lower, although a dicey trading update fro...

“Attaining the key Chinese patent is an important milestone. This adds to Imugene’s portfolio of B-cell immunotherapies, and this will protect them in one of the world’s largest HER-2 positive gastric cancer markets until 2036,” Imugene’s M...

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.

The Imugene Limited (ASX: IMU) share price is on course to start the week with a gain. In early trade, the immuno-oncology company’s shares are up 4% to 53.5 cents. Why is the Imugene share price charging higher? The catalyst for the rise...

Imugene (IMU) receives US FDA Investigational New Drug (IND) approval for two new drug candidates The first approval gives Imugene permission to begin patient recruitment and dosing for the nextHERIZON study in advanced gastric cancer The...

Today, the S&P/ASX 200 Index (ASX: XJO) experienced a bumpy ride as it bounced between positive and negative. Unfortunately, it was on the negative side of the fence that the market decided to settle on by the end of the day. In specif...

The ASX 200 finished lower by 0.28% today, as investors turn cautious ahead of the Fed’s CPI release this Friday (US time). Overnight, US and EU markets rose following Pfizer’s announcement that three doses of its jab could protect against...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.4% to 7,245.1 points. Four ASX shares that are climbing more than most today are listed below...

The Imugene Limited (ASX: IMU) share price is up today on the back of a positive cancer treatment update. Shares in the biopharma company are currently trading at 50 cents, up 5.26%. Let’s take a look at what’s going on at Imugene. Wha...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Imugene (IMU) doses its second patient in the phase one clinical trial of its CHECKvacc drug candidate on patients with triple negative breast cancer (TNBC) The study aims to evaluate the safety and efficacy of the CHECKvacc drug when admi...

“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with TNBC,” says CEO and MD.

Shares in biopharma company Imugene Limited (ASX: IMU) are inching lower in afternoon trade and are now changing hands at 48.8 cents apiece, down 4.41%. Whilst there’s been no market-sensitive information from the company today, its shar...

In the December 2021 quarterly rebalance Imugene will be added to the S&P/ASX 200 Index and Archer Materials added to the S&P/ASX All Technology Index.

Alloggio Group (ASX:ALO), didn’t have a positive debut on the ASX last week but that didn’t stop one director from buying more on market. The holiday accommodation manager listed at 20 cents per share but fell as low as 15 cents on debut am...

Today, the S&P/ASX 200 Index (ASX: XJO) made an effort to recoup its early morning losses but was unable to overcome the downward pressure. At the end of the session, the benchmark index finished 0.15% lower to 7,225.2 points. While th...

The ASX 200 closed in the red for the third time in four sessions on Thursday, but an afternoon rally saw it finish just 0.15% lower on the day. As markets reassess the outlook for tighter monetary policy and ongoing COVID-19 disruptions, t...

Today, the S&P/ASX 200 Index (ASX: XJO) partially bounced back from yesterday’s Omicron-induced panic. At the end of the session, the benchmark index finished 0.22% higher to 7,256 points. The gains were far-reaching across the Aussie...

After climbing more than 1% in morning trade, local large caps lost ground in the afternoon session as the ASX 200 finished up eking out a 0.22% gain. The big end of town was clearly outshone by the microcap Emerging Companies index, which...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

The Imugene Limited (ASX: IMU) share price is flat at 52.5 cents in early trade today after finishing 4.5% in the red yesterday. However, shares in the biopharma company have climbed 17% in the past month. They are also up 81% since the...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

After falling by ~0.8% on Tuesday, the ASX 200 struggled for traction in Wednesday trade to finish 0.15%. Now that he’s shepherded the US economy through a pandemic, J-Pow is back for a second term. And while he’s not about to hike rates wi...

As Stockhead’s Josh Chiat reported this morning, reports of an industrial production slowdown in the Middle Kingdom may have been greatly exaggerated. In fact, the latest update from the People’s Bank of China raised the possibility to more...

The success of trials of the company's cancer immunotherapy drug to date has encouraged Roth Capital Partners to place a buy recommendation and raise Imugene's price target to A$0.71 from A$0.62.

Today, the S&P/ASX 200 Index (ASX: XJO) managed to deliver a positive session despite weakness in markets overnight. At the end of the day, the benchmark index finished 0.13% higher at 7,379.2 points. Despite another lacklustre day for...

The ASX 200 rebounded by 0.13% today, after posting losses over the last two days. Healthcare, Real Estate and Consumer Staples were the best sectors rising by 1% each, while Energy was the main laggard losing 1%. Falls in energy stocks fol...

Imugene (ASX:IMU) has announced a new supply agreement with Pfizer and Merck for a trial involving their PBS-listed PD-L1 BAVENCIO (avelumab).

The ASX 200 continues its slide, down by 0.63% today after a 0.67% fall yesterday. Stocks were sold off following an ABS data release showing a 3.4% surge in white collar salaries in the year ending September. Overall wages also rose 2.2 pe...